Alexion announces plans to initiate Phase 3 Study of ULTOMIRIS (ravulizumab-cwvz) in hospitalised patients with severe COVID-19

Alexion has announced plans to initiate Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19. (Credit: Pete Linforth from Pixabay)